Though there is evidence that diabetes patients with established coronary artery disease may gain benefits of reduced ischaemic risk from long-term DAPT compared to aspirin alone [33, 34], there is currently no evidence for use of P2Y12 inhibitors for primary prevention of cardiovascular events in any population, including in those with diabetes. This evidence concerns the gene P2RY12 and diabetes mellitus.